Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:
“Hot off the press—Our Dr. John Heymach from MD Anderson Cancer Center presents on BEAMION-Lung 1. Oral zongertinib 120 mg QD in previously-treated HER2+ mNSCLC:
ORR 71%
mPFS 12.4 mo
Intracranial ORR 41%
No ILD, only 1 patient w/ grade 3 diarrhea.”
“Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer”
Authors: John V. Heymach et al.
